Please login to the form below

Not currently logged in
Email:
Password:

Biotech and vaccines focus for sanofi-aventis

French drugs maker sanofi-aventis has announced that it plans to shift its emphasis to biotechnology and vaccine production

French drugs maker sanofi-aventis (S-A) has announced that by 2014 it plans to shift its emphasis to biotechnology and vaccine production in France, and away from the chemical production of drugs.

The company is presenting employees with its plans to invest €150m in the transfer, which will entail training programmes and the creation of the group's third largest European vaccine production site.

The company said the move reflects its shift in business from producing drugs through synthetic chemistry following patent expirations of several key drugs.

The new activities will create jobs locally, the company said.

31st March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics